摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2,2,4-trimethyl-1,2-dihydro-naphthalen-1-yl)-3H-imidazole-4-carboxylic acid methyl ester | 1034920-08-5

中文名称
——
中文别名
——
英文名称
3-(2,2,4-trimethyl-1,2-dihydro-naphthalen-1-yl)-3H-imidazole-4-carboxylic acid methyl ester
英文别名
methyl 3-(2,2,4-trimethyl-1H-naphthalen-1-yl)imidazole-4-carboxylate
3-(2,2,4-trimethyl-1,2-dihydro-naphthalen-1-yl)-3H-imidazole-4-carboxylic acid methyl ester化学式
CAS
1034920-08-5
化学式
C18H20N2O2
mdl
——
分子量
296.369
InChiKey
VSUXWGHCSNCSOU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    22
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    44.1
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • ORGANIC COMPOUNDS
    申请人:Adams Christopher
    公开号:US20100048562A1
    公开(公告)日:2010-02-25
    The present invention provides a compound of formula I: said compound is inhibitor of aldosterone synthase (CYP11B2), and/or 11 beta-hydroxylase (CYP11B1), and/or aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase, aromatase, or CYP11B1. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction. Finally, the present invention also provides a pharmaceutical composition.
    本发明提供了一种公式I的化合物:该化合物是醛固酮合成酶(CYP11B2)和/或11β-羟化酶(CYP11B1)和/或芳香化酶的抑制剂,因此可用于治疗由醛固酮合成酶、芳香化酶或CYP11B1介导的疾病或疾病。因此,公式I的化合物可用于治疗低钾血症、高血压、充血性心力衰竭、肾衰竭,特别是慢性肾衰竭、再狭窄、动脉粥样硬化、X综合征、肥胖症、肾病、心肌梗死后、冠心病、胶原形成增加、高血压和内皮功能障碍后的纤维化和重塑。最后,本发明还提供了一种制药组合物。
  • Organic compounds
    申请人:Adams Christopher
    公开号:US08436035B2
    公开(公告)日:2013-05-07
    The present invention provides a compound of formula I: said compound is inhibitor of aldosterone synthase (CYP11B2), and/or 11 beta-hydroxylase (CYP11B1), and/or aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase, aromatase, or CYP11B1. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial dysfunction. Finally, the present invention also provides a pharmaceutical composition.
    本发明提供了一种I式化合物:所述化合物是醛固酮合成酶(CYP11B2)和/或11-β-羟化酶(CYP11B1)和/或芳香化酶的抑制剂,因此可用于治疗由醛固酮合成酶、芳香化酶或CYP11B1介导的疾病或疾患。因此,I式化合物可用于治疗低钾血症、高血压、充血性心力衰竭、肾衰竭,特别是慢性肾衰竭、再狭窄、动脉粥样硬化、X综合征、肥胖症、肾病、心肌梗死后、冠心病、胶原形成增加、高血压和内皮功能障碍后的纤维化和重塑。最后,本发明还提供了一种制药组合物。
  • Imidazoles as aldosterone synthase inhibitors
    申请人:Novartis AG
    公开号:EP2213668A2
    公开(公告)日:2010-08-04
    The present invention provides a compound of formula I: said compound is inhibitor of aldosterone synthase (CYP11B2), and/or 11beta-hydroxylase (CYP11B1), and/or aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase, aromatase, or CYP11B1. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collage, fibrosis and remodeling following hypertension and endothelial dysfunction. Finally, the present invention also provides a pharmaceutical composition.
    本发明提供了一种式 I 的化合物: 所述化合物是醛固酮合成酶(CYP11B2)和/或 11beta-羟化酶(CYP11B1)和/或芳香化酶的抑制剂,因此可用于治疗由醛固酮合成酶、芳香化酶或 CYP11B1 介导的紊乱或疾病。因此,式 I 化合物可用于治疗低钾血症、高血压、充血性心力衰竭、肾功能衰竭(尤其是慢性肾功能衰竭)、再狭窄、动脉粥样硬化、X 综合征、肥胖症、肾病、心肌梗塞后、冠心病、高血压后胶原形成增加、纤维化和重塑以及内皮功能障碍。最后,本发明还提供了一种药物组合物。
  • IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS
    申请人:NOVARTIS AG
    公开号:EP2094680A2
    公开(公告)日:2009-09-02
  • US8436035B2
    申请人:——
    公开号:US8436035B2
    公开(公告)日:2013-05-07
查看更多